Health · 5 views

FDA approves label expansion for Vyvgart, Vyvgart Hytrulo for generalized myasthenia gravis

The U.S. Food and Drug Administration has approved a label expansion for Vyvgart (efgartigimod alfa-fcab) and Vyvgart Hytrulo (efgartigim…

Source Medical Xpress AI Summary Updated May 19, 2026

Story intelligence Beta

Freshness Stale Updated May 19, 2026

Confidence Limited Single-outlet story

Coverage Single outlet

Views 5 Community interest

Read time 1 min ~37 words

AI Summary

The U.S. Food and Drug Administration has approved a label expansion for Vyvgart (efgartigimod alfa-fcab) and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with (gMG). The expanded approval was granted to argenx.

Read full article on Medicalxpress

AI summaries can be wrong sometimes—always verify important details using the source article.